Table 1.
Patients with coronary artery spasms
| Case | Age (years) |
Sex | Combined disease | Smoking; Brinkman index | Beta-blocker Y/N | Calcium channel | AF type | CHADS2 score | CHA2DS2-VASc score | LAD (mm) | When spasms were observed | Localization of ST-elevation in the 12-lead ECG | Bradycardia Y/N |
Hypotension Y/N |
Anesthesia |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 69 | M | None | 2880 | Y | N | Per AF | 0 | 1 | 37 | 2 h after CA | V1-5, aVR | N | Y | Midazolam + dexmedetomidine |
| 2 | 65 | M | HTN | 900 | Y | Y | PAF | 1 | 2 | 38 | When sheath was pulled out after | II, III, aVF | Y | Y | Propofol |
| 3 | 41 | M | None | 60 | N | N | PAF | 0 | 0 | 32 | After Brockenbrough | II, III, aVF | N | N | Propofol |
| 4 | 74 | M | DM, DL | 600 | N | N | PAF | 1 | 2 | 32 | After Brockenbrough | II, III, aVF | N | N | Midazolam + dexmedetomidine |
| 5 | 74 | F | HTN, DL | 540 | N | N | PAF | 1 | 3 | 45 | After Brockenbrough | II, III, aVF | Y | Y | Midazolam + dexmedetomidine |
| 6 | 72 | M | None | 780 | N | N | PAF | 0 | 1 | 28 | After Brockenbrough | II, III, aVF | N | N | Midazolam + dexmedetomidine |
| 7 | 66 | F | HTN, DL, BA | 0 | Y | Y | PAF | 1 | 3 | 28 | After Brockenbrough | II, III, aVF | N | Y | Midazolam + dexmedetomidine |
| 8 | 66 | M | HTN, DL | 540 | N | Y | Per AF 2nd | 1 | 2 | 39 | After Brockenbrough | II, III, aVF | Y | Y | Midazolam + dexmedetomidine |
| 9 | 63 | M | None | 900 | N | N | Per AF | 0 | 0 | 42 | After Brockenbrough | II, III, aVF | Y | N | Midazolam + dexmedetomidine |
AF atrial fibrillation, BA bronchial asthma, CA, catheter ablation, Dex dexmedetomidine, DL dyslipidemia, DM diabetes mellitus, HTN hypertension, LAD left atrial diameter, PAF paroxysmal atrial fibrillation, Per AF persistent atrial fibrillation